ARTICLE | Clinical News
hPTH: Phase I data
July 16, 2007 7:00 AM UTC
In an open-label, dose-ranging, Dutch Phase I trial in 48 healthy post-menopausal women, once-daily transdermal hPTH (1-34) was well tolerated for 7 days and had a similar safety profile to subcutaneo...